News >

Subset of BRAF non-V600-Mutant mCRC Is Potentially More Sensitive to Anti-EGFR Therapy

Caroline Seymour
Published: Wednesday, Sep 18, 2019

Patients with metastatic colorectal cancer (mCRC) who harbored BRAF non-V600, RAS-dependent mutations were more likely to respond to anti-EGFR therapy versus those with BRAF non-V600, RAS-independent mutations, according to results of a multicenter pooled analysis published in Clinical Cancer Research.1

-mutant mCRC.


  1. Patients with metastatic colorectal cancer harboring certain BRAF mutations may respond to anti-EGFR therapy. American Association for Cancer Research. Published September 12, 2019. Accessed September 12, 2019.
  2. Yaeger R, Kotani D. Mondaca S, et al. Response to anti-EGRR therapy in patients with BRAF non-V600-mutant metastatic colorectal cancer [published online September 12, 2019]. Clin Cancer Res. doi: 10.1158/1078-0432.CCR-19-2004.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication